Ensysce Biosciences Reports Q4 and Full Year 2025 Results

Clinical and regulatory milestones position PF614 for late-stage advancement

Mar. 30, 2026 at 8:51pm

Got story updates? Submit your updates here. ›

Ensysce Biosciences, a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2025.

Why it matters

As a clinical-stage biotech company, Ensysce's financial performance and pipeline progress are closely watched by investors and the pharmaceutical industry. The company's focus on developing abuse-deterrent drug formulations is also of interest given the ongoing opioid crisis.

The details

Ensysce highlighted several key clinical and regulatory milestones achieved during the fourth quarter that positioned its lead candidate PF614 for late-stage advancement. The company did not provide specific financial figures in the release.

  • Ensysce reported results for the fourth quarter and full year ended December 31, 2025.

The players

Ensysce Biosciences, Inc.

A clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose.

PF614

Ensysce's lead drug candidate positioned for late-stage advancement.

Got photos? Submit your photos here. ›

The takeaway

Ensysce's progress with its abuse-deterrent drug formulations is noteworthy as the company aims to address the ongoing opioid crisis through innovative pharmaceutical solutions.